High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Memory chipmaker Micron Technology leapfrogged South Korean rival SK Hynix to become the 12th most-valuable company in the world, in a rally that has more than tripled the stock this year. Shares jumped another 7.5% Monday to $1,044, lifting the...
The UAE launch marks the start of Novo's global rollout, with additional launches planned later this year.
The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become apparent this year.
Eli Lilly's pipeline is an embarrassment of riches.
Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.
Bristol-Myers Squibb has underperformed the Dow recently, yet analysts remain moderately optimistic about the stock’s prospects.
While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC.
The rest of the stocks in the IHE ETF make it an unappealing way to play the pharma industry here.
An upcoming trial result could change how investors think about the weight-loss drug market.
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy now for long term growth. Eli Lilly and Company (NYSE:LLY) announced on May 28 that its full obesity medicine portfolio would now be covered by all three of the largest pharmacy benefit managers in the nation. This considerably expands the number of Americans […]
PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline.
Deals total $2.5 trillion so far this year. Casinos and home builders are hot right now, but watch for more action in biotechs and financials.
CVS Caremark has moved to cover Eli Lilly's full obesity drug portfolio, including the newly approved oral therapy Foundayo. The decision aligns CVS Caremark with other major U.S. pharmacy benefit managers that now include Eli Lilly's obesity medicines on their formularies. Coverage spans both Foundayo and injectable products such as Zepbound, widening insurance access across key distribution channels. Eli Lilly (NYSE:LLY) has become a central player in obesity care, with a portfolio that...
Eli Lilly (LLY) just did something worth paying attention to. With CVS Caremark announcing coverage of both Zepbound and newly approved Foundayo starting this summer, all three of the largest U.S. pharmacy benefit managers now cover Lilly’s complete obesity medicine portfolio. That’s a clean sweep ...
David Ricks was addressing the pharmaceutical titan's latest hot product.
Positive late-stage results may support an expanded use of the therapy.
We just covered the 10 Best Stocks to Buy Right Now According to AI and Eli Lilly and Company (NYSE:LLY) ranks 4th on this list. Eli Lilly and Company (NYSE:LLY) is a premier global pharmaceutical corporation dedicated to discovering, developing, and manufacturing innovative human medicines across multiple therapeutic areas. The company’s primary growth catalyst is […]
Lilly shares soared more than 18% in May.
Hanmi will receive $75m upfront and may earn up to $1.185bn in milestone payments for development and approvals.
Eli Lilly and Company (NYSE:LLY) announced positive data from its Phase 3 LIBRETTO-432 trial, showing that Retevmo significantly lowered the risk of disease recurrence or death in patients with early-stage RET fusion-positive non-small cell lung cancer (NSCLC) following initial treatment. The study found that treatment with Retevmo (selpercatinib) reduced the risk of recurrence or death by 83% compared with placebo, highlighting the drug’s potential role as an adjuvant therapy for patients with
Eli Lilly (LLY) and Company announced results from the Phase 3 Libretto-432 clinical trial of Retevmo as adjuvant therapy versus placebo in patients with early-stage rearranged during transfection fusion-positive non-small cell lung cancer, NSCLC. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in investigator-assessed event-free survival with selpercatinib reducing the risk of disease recurrence or death by 83% versus pl
Recent performance context for Eli Lilly (LLY) Eli Lilly (LLY) has drawn investor attention after a period where the stock rose about 15% over the past month and about 10% over the past 3 months, alongside strong reported revenue and net income figures. See our latest analysis for Eli Lilly. That recent 14.7% 30 day share price return comes on top of a 48.9% total shareholder return over the past year and a very large 5 year total shareholder return, so momentum has been building over both...
Investing.com -- GLP-1 weight-loss and diabetes drugs may have a future role in cancer prevention and treatment, according to new research highlighted by Citi ahead of the 2026 American Society of Clinical Oncology (ASCO) meeting, adding another potential growth avenue to an already booming drug class.
Shingles is no minor inconvenience. Ask anyone who has had it and they will tell you the burning, nerve-rattling pain can last for days. But what if surviving shingles was only half the battle? New research suggests the virus behind it could raise your risk of stroke and dementia years after the ...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
